Multiple Myeloma

Shaji Kumar MD and Sagar Lonial MD review and share their expert perspectives on key findings in multiple myeloma presented at the 2017 ASH annual meeting.

Share

Program Content

Activities

  • IFM 2013-01: PCD in RR MM
    Phase II IFM 2013-01: Pomalidomide/Cyclophosphamide/Dexamethasone in Relapsed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

  • BCMA-CART in R/R MM
    BCMA-Targeted CAR T-Cells ± Cyclophosphamide in Relapsed/Refractory Multiple Myeloma: Phase I Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

  • GEM-CESAR: KRD + ASCT in SMM
    Phase II GEM-CESAR: KRd + ASCT in High-Risk Smoldering Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2017

  • ALCYONE: Dara + VMP
    ALCYONE: Daratumumab Plus VMP vs VMP Alone in Newly Diagnosed, Transplantation-Ineligible Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2017

  • Anti-BCMA CART in RRMM
    bb2121 Anti-BCMA CAR T-Cell Therapy in Relapsed/Refractory Myeloma: Updated Phase I Results
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

  • CD19/BCMA CAR T-cells
    Pilot Study: Combined CD19- and BCMA-Targeted CAR T-Cells in Relapsed/Refractory Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

  • EMN02/HO95: Double vs Single ASCT
    Double Vs Single ASCT in Newly Diagnosed Multiple Myeloma: An Analysis of the EMN02/HO95 Phase III Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2017

  • MCARH171 CAR T-Cells in MM
    Phase I Study: MCARH171 BCMA-Targeted CAR T-Cells in Advanced Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • Phase Ib Pavo: SC Dara in R/R MM
    Phase Ib PAVO: Subcutaneous Administration of Coformulated Daratumumab + rHuPH20 in Relapsed/Refractory Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • CENTAURUS: Dara in SMM
    CENTAURUS: Randomized Study of Daratumumab Dosing in Intermediate- or High-Risk Smoldering Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2017

  • LEN-ELO Maintenance for MM
    Elotuzumab/Lenalidomide/Dexamethasone Maintenance After ASCT in Patients With MM: Preliminary Results From a Phase II Study
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2017

  • MM: Ixazomib Maintenance
    Long-term Ixazomib Maintenance in ASCT-Ineligible Patients With Newly Diagnosed MM: Pooled Analysis of 4 Phase I/II Trials
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2017

  • POLLUX Follow-up
    Daratumumab + Rd vs Rd Alone in Relapsed/Refractory Myeloma: Extended Follow-up From POLLUX
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2017

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology